Investigative ophthalmology & visual science · 2026
Neuritin1 Cis-Regulatory Elements Enable Gene Expression Preferentially in Retinal Ganglion Cells.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Talla Venu, Koilkonda Rajeshwari, Kinane Chaimaa, Panchal Moxa, Khuu Tamdan, Park Kevin K
Аннотация
PURPOSE: Retinal ganglion cells (RGCs) are essential for visual signal transmission, yet they are vulnerable to injury and degeneration. Gene modulation in RGCs using adeno-associated virus (AAV) offers a promising avenue for neuroprotection and regeneration, but promoters lack sufficient RGC specificity, limiting the precision needed for preclinical studies. This study aims to identify novel promoter-enhancer combinations (PECs) to achieve gene expression preferentially in RGCs.
METHODS: We evaluated existing transcriptomic data to identify neuritin 1 (Nrn1) as a gene with highly restricted RGC expression in the retina. Synthetic PECs derived from human and mouse Nrn1 loci were incorporated into AAV2 vectors driving expression of a nuclear-targeted reporter GreenLantern. AAVs were delivered via intravitreal injection into C57BL6/J mice, and transduction efficiency and RGC specificity were evaluated in both young and aged retinas and those subjected to intraorbital optic nerve crush (ONC), using immunohistochemistry and quantitative analysis of RBPMS+ cells.
RESULTS: We found that AAV2 with a human Nrn1-PEC drives gene expression in RGCs. Quantitative analysis revealed that over 83% of transduced cells were RBPMS+, indicating robust RGC selectivity and significantly outperforming ubiquitous promoters. Notably, the Nrn1-PEC retained strong and selective transgene expression in RGCs in aged mice and following ONC, demonstrating its resilience under aged and injury conditions.
CONCLUSIONS: The Nrn1-PEC enables efficient and injury-resilient gene expression in RGCs, addressing a key limitation in cell-specific targeting. This AAV-incorporated PEC offers a robust platform for evaluating neuroprotective interventions and accelerates the translational development of gene therapies for glaucoma and other optic neuropathies.
METHODS: We evaluated existing transcriptomic data to identify neuritin 1 (Nrn1) as a gene with highly restricted RGC expression in the retina. Synthetic PECs derived from human and mouse Nrn1 loci were incorporated into AAV2 vectors driving expression of a nuclear-targeted reporter GreenLantern. AAVs were delivered via intravitreal injection into C57BL6/J mice, and transduction efficiency and RGC specificity were evaluated in both young and aged retinas and those subjected to intraorbital optic nerve crush (ONC), using immunohistochemistry and quantitative analysis of RBPMS+ cells.
RESULTS: We found that AAV2 with a human Nrn1-PEC drives gene expression in RGCs. Quantitative analysis revealed that over 83% of transduced cells were RBPMS+, indicating robust RGC selectivity and significantly outperforming ubiquitous promoters. Notably, the Nrn1-PEC retained strong and selective transgene expression in RGCs in aged mice and following ONC, demonstrating its resilience under aged and injury conditions.
CONCLUSIONS: The Nrn1-PEC enables efficient and injury-resilient gene expression in RGCs, addressing a key limitation in cell-specific targeting. This AAV-incorporated PEC offers a robust platform for evaluating neuroprotective interventions and accelerates the translational development of gene therapies for glaucoma and other optic neuropathies.